Mediwound Ltd (MDWD)

Currency in USD
18.740
+0.120(+0.64%)
Closed·
18.7400.000(0.00%)
·
MDWD is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
18.40018.900
52 wk Range
14.14022.505
Key Statistics
Prev. Close
18.62
Open
18.67
Day's Range
18.4-18.9
52 wk Range
14.14-22.505
Volume
53.91K
Average Volume (3m)
76.76K
1-Year Change
6.06%
Book Value / Share
3.91
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
MDWD Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
31.500
Upside
+68.09%
Members' Sentiments
Bearish
Bullish
ProTips
4 analysts have revised their earnings upwards for the upcoming period

Mediwound Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Neutral
Moving Averages
Buy

Mediwound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

Employees
111

Mediwound Ltd Earnings Call Summary for Q4/2024

  • Q4 2024 EPS of -$0.36 beat expectations; revenue reached $5.84M, slightly above forecast
  • Full-year 2024 revenue increased to $20.2M from $18.7M in 2023; net loss of $30.2M or $3.03 per share
  • NexoBrid 2025 revenue projected at $24M; Phase 3 VLU Global Trial for EscharEx interim analysis expected mid-2026
  • Stock closed at $19.19, down 0.42% pre-market despite earnings beat; analysts maintain bullish outlook
  • Strong liquidity with current ratio of 2.11; cash position of $43.6M at year-end
Last Updated: 19/03/2025, 13:40
Read Full Transcript

Compare MDWD to Peers and Sector

Metrics to compare
MDWD
Peers
Sector
Relationship
P/E Ratio
−11.7x28.3x−0.6x
PEG Ratio
−0.330.290.00
Price/Book
4.8x2.5x2.6x
Price / LTM Sales
11.5x2.2x3.2x
Upside (Analyst Target)
70.8%30.2%41.8%
Fair Value Upside
Unlock1.1%5.1%Unlock

Analyst Ratings

6 Buy
0 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 31.500
(+68.09% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy36.00+92.10%31.00Maintain21/11/2025
Oppenheimer
Buy34.00+81.43%-New Coverage02/06/2025
H.C. Wainwright
Buy31.00+65.42%25.00Maintain22/05/2025
Alliance Global Partners
Buy25.00+33.40%-New Coverage02/05/2025
Craig-Hallum
Buy39.00+108.11%-New Coverage28/02/2025

Earnings

Latest Release
Nov 20, 2025
EPS / Forecast
-0.24 / -0.81
Revenue / Forecast
5.43M / 6.56M
EPS Revisions
Last 90 days

People Also Watch

13.44
RDCM
+0.52%
43.18
ITRN
-0.80%
1.185
RDHL
+3.04%
1.7900
MBAI
-3.24%
3.00
NNOX
-2.91%

FAQ

What Is the Mediwound (MDWD) Share Price Today?

The live Mediwound share price today is 18.740

What Stock Exchange Does Mediwound (MDWD) Trade On?

Mediwound is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Mediwound?

The stock symbol (also called a 'ticker') for Mediwound is "MDWD."

What Is the Current Mediwound Market Cap?

As of today, Mediwound market capitalisation is 240.27M.

What Is Mediwound's (MDWD) Earnings Per Share (TTM)?

The Mediwound EPS is currently -1.90 (Trailing Twelve Months).

When Is the Next Mediwound Earnings Date?

Mediwound's next earnings report will be released on 12 Mar 2026.

Is MDWD a Buy or Sell From a Technical Analyst Perspective?

Based on today's Mediwound moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has Mediwound Stock Split?

Mediwound has split 1 times. (See the MDWD stock split history page for full effective split date and price information.)

How Many Employees Does Mediwound Have?

Mediwound has 111 employees.

What is the current trading status of Mediwound (MDWD)?

As of 24 Dec 2025, Mediwound (MDWD) is trading at a price of 18.740, with a previous close of 18.620. The stock has fluctuated within a day range of 18.400 to 18.900, while its 52-week range spans from 14.140 to 22.505.

What Is Mediwound (MDWD) Price Target According to Analysts?

The average 12-month price target for Mediwound is USD31.5, with a high estimate of USD39 and a low estimate of USD25. 6 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +68.09% Upside potential.

What Is the MDWD Premarket Price?

MDWD's last pre-market stock price is 19.180. The pre-market share volume is 830.000, and the stock has decreased by 0.560, or 3.010%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.